Infantile hemangiomas (IHs) are benign vascular tumors. Clinical history and physical examination are the most important factors for diagnosis, with most IHs having a typical presentation. Treatment is required for some IHs that cause significant cosmetic deformity or functional compromise. Propranolol is the first-line treatment of most IHs. Ongoing research is increasing our understanding of the pathophysiology of these tumors and should help to identify future potential therapeutic targets.
Keywords: Glucose transporter 1 (GLUT 1); Head and neck; PHACES; Pediatric hemangioma; Propranolol; Subglottic hemangioma.
Copyright © 2013 Elsevier Inc. All rights reserved.